Why, who and how should perform liver biopsy in chronic liver diseases

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=3396 & v=14

World J Gastroenterol 2008 June;14(21):3396-3402

Why, who and how should perform liver biopsy in chronic liver diseases

Sporea I, Popescu A, Sirli R.

Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara

700736, Romania. isporea@...

Chronic viral hepatitis is a common disease in the general population. During

chronic hepatitis, the prognosis and clinical management are highly dependent on

the extent of liver fibrosis. The fibrosis evaluation can be performed by

FibroTest (using serological markers), by Elastography or FibroScan (a

noninvasive percutaneous technique using the elastic properties of the hepatic

tissue) and by liver biopsy (LB), considered to be the " gold standard " .

Currently, there are three techniques for performing LB: percutaneous,

transjugular and laparoscopic. The percutaneous LB can be performed blind,

ultrasound (US) guided or US assisted. There are two main categories of

specialists who perform LB: gastroenterologists (hepatologists) and

radiologists, and the specialty of the individual who performs the LB determines

if the LB is performed under ultrasound guidance or not. There are two types of

biopsy needles used for LB: cutting needles (Tru-Cut, Vim-Silverman) and suction

needles (Menghini, Klatzkin, Jamshidi). The rate of major complications after

percutaneous LB ranges from 0.09% to 2.3%, but the echo-guided percutaneous

liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis

(cost-effective as compared to blind biopsy) and the rate of complications seems

to be related to the experience of the physician and the type of the needle used

(Menghini type needle seems to be safer). Maybe, in a few years we will use

non-invasive markers of fibrosis, but at this time, most authorities in the

field consider that the LB is useful and necessary for the evaluation of chronic

hepatopathies, despite the fact that it is not a perfect test.

_________________________________________________________________

Now you can invite friends from Facebook and other groups to join you on Windows

Live™ Messenger. Add now.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_AddNow_Now

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=3396 & v=14

World J Gastroenterol 2008 June;14(21):3396-3402

Why, who and how should perform liver biopsy in chronic liver diseases

Sporea I, Popescu A, Sirli R.

Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara

700736, Romania. isporea@...

Chronic viral hepatitis is a common disease in the general population. During

chronic hepatitis, the prognosis and clinical management are highly dependent on

the extent of liver fibrosis. The fibrosis evaluation can be performed by

FibroTest (using serological markers), by Elastography or FibroScan (a

noninvasive percutaneous technique using the elastic properties of the hepatic

tissue) and by liver biopsy (LB), considered to be the " gold standard " .

Currently, there are three techniques for performing LB: percutaneous,

transjugular and laparoscopic. The percutaneous LB can be performed blind,

ultrasound (US) guided or US assisted. There are two main categories of

specialists who perform LB: gastroenterologists (hepatologists) and

radiologists, and the specialty of the individual who performs the LB determines

if the LB is performed under ultrasound guidance or not. There are two types of

biopsy needles used for LB: cutting needles (Tru-Cut, Vim-Silverman) and suction

needles (Menghini, Klatzkin, Jamshidi). The rate of major complications after

percutaneous LB ranges from 0.09% to 2.3%, but the echo-guided percutaneous

liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis

(cost-effective as compared to blind biopsy) and the rate of complications seems

to be related to the experience of the physician and the type of the needle used

(Menghini type needle seems to be safer). Maybe, in a few years we will use

non-invasive markers of fibrosis, but at this time, most authorities in the

field consider that the LB is useful and necessary for the evaluation of chronic

hepatopathies, despite the fact that it is not a perfect test.

_________________________________________________________________

Now you can invite friends from Facebook and other groups to join you on Windows

Live™ Messenger. Add now.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_AddNow_Now

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=3396 & v=14

World J Gastroenterol 2008 June;14(21):3396-3402

Why, who and how should perform liver biopsy in chronic liver diseases

Sporea I, Popescu A, Sirli R.

Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara

700736, Romania. isporea@...

Chronic viral hepatitis is a common disease in the general population. During

chronic hepatitis, the prognosis and clinical management are highly dependent on

the extent of liver fibrosis. The fibrosis evaluation can be performed by

FibroTest (using serological markers), by Elastography or FibroScan (a

noninvasive percutaneous technique using the elastic properties of the hepatic

tissue) and by liver biopsy (LB), considered to be the " gold standard " .

Currently, there are three techniques for performing LB: percutaneous,

transjugular and laparoscopic. The percutaneous LB can be performed blind,

ultrasound (US) guided or US assisted. There are two main categories of

specialists who perform LB: gastroenterologists (hepatologists) and

radiologists, and the specialty of the individual who performs the LB determines

if the LB is performed under ultrasound guidance or not. There are two types of

biopsy needles used for LB: cutting needles (Tru-Cut, Vim-Silverman) and suction

needles (Menghini, Klatzkin, Jamshidi). The rate of major complications after

percutaneous LB ranges from 0.09% to 2.3%, but the echo-guided percutaneous

liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis

(cost-effective as compared to blind biopsy) and the rate of complications seems

to be related to the experience of the physician and the type of the needle used

(Menghini type needle seems to be safer). Maybe, in a few years we will use

non-invasive markers of fibrosis, but at this time, most authorities in the

field consider that the LB is useful and necessary for the evaluation of chronic

hepatopathies, despite the fact that it is not a perfect test.

_________________________________________________________________

Now you can invite friends from Facebook and other groups to join you on Windows

Live™ Messenger. Add now.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_AddNow_Now

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=3396 & v=14

World J Gastroenterol 2008 June;14(21):3396-3402

Why, who and how should perform liver biopsy in chronic liver diseases

Sporea I, Popescu A, Sirli R.

Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara

700736, Romania. isporea@...

Chronic viral hepatitis is a common disease in the general population. During

chronic hepatitis, the prognosis and clinical management are highly dependent on

the extent of liver fibrosis. The fibrosis evaluation can be performed by

FibroTest (using serological markers), by Elastography or FibroScan (a

noninvasive percutaneous technique using the elastic properties of the hepatic

tissue) and by liver biopsy (LB), considered to be the " gold standard " .

Currently, there are three techniques for performing LB: percutaneous,

transjugular and laparoscopic. The percutaneous LB can be performed blind,

ultrasound (US) guided or US assisted. There are two main categories of

specialists who perform LB: gastroenterologists (hepatologists) and

radiologists, and the specialty of the individual who performs the LB determines

if the LB is performed under ultrasound guidance or not. There are two types of

biopsy needles used for LB: cutting needles (Tru-Cut, Vim-Silverman) and suction

needles (Menghini, Klatzkin, Jamshidi). The rate of major complications after

percutaneous LB ranges from 0.09% to 2.3%, but the echo-guided percutaneous

liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis

(cost-effective as compared to blind biopsy) and the rate of complications seems

to be related to the experience of the physician and the type of the needle used

(Menghini type needle seems to be safer). Maybe, in a few years we will use

non-invasive markers of fibrosis, but at this time, most authorities in the

field consider that the LB is useful and necessary for the evaluation of chronic

hepatopathies, despite the fact that it is not a perfect test.

_________________________________________________________________

Now you can invite friends from Facebook and other groups to join you on Windows

Live™ Messenger. Add now.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_AddNow_Now